

References:

1. Akerman, S., Holland, P.R., Lasalandra, M.P., and Goadsby, P.J. (2013, September). Endocannabinoids in the brainstem modulate dural trigeminovascular nociceptive traffic via CB1 and “triptan” receptors: implications in migraine. *Journal of Neuroscience*, 33(37), 14869-77.
2. Akirav, I. (2013). Targeting the endocannabinoid system to treat haunting traumatic memories. *Frontiers in Behavioral Neuroscience*, 7, 124. Retrieved from <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3776936/>.
3. Amtmann, D., Weydt, P., Johnson, K.L., Jensen, M.P., and Carter, G.T. (2004). Survey of cannabis use in patients with amyotrophic lateral sclerosis. *The American Journal of Hospice and Palliative Care*, 21(2), 94-104.
4. Andries, A., Frystyk, J., Flyvbjerg, A., and Stoving, R.K. (2014, January). Dronabinol in severe, enduring anorexia nervosa: a randomized controlled trial. *The International Journal of Eating Disorders*, (47)1, 18-23.
5. Appendino, G., Gibbons, S., Giana, A., Pagani, A., Grassi, G., Stavri, M., Smith, E., and Rahman, M.M. (2008, August). Antibacterial cannabinoids from *Cannabis sativa*: a structure-activity study. *Journal of Natural Products*, 71(8), 1427-30.
6. Arevalo-Martin, A., Garcia-Ovejero, D., Sierra-Palomares, Y., Paniagua-Torija, B., Gonzalez-Gil, I., Oretaga-Gutierrez, S., and Molina-Holgado, E. (2012). Early endogenous activation of CB1 and CB2 receptors after spinal cord injury is a protective response involved in spontaneous recovery. *PLoS One*, 7(11), e49057.
7. Avraham, Y., Grigoriadis, N., Poutahidis, T., Vorobiev, L., Magen, I., Ilan, Y., Mechoulam, R., and Berry, E. (2011, April). Cannabidiol improves brain and liver function in a fulminant hepatic failure-induced model of hepatic encephalopathy in mice. *British Journal of Pharmacology*, 162(7), 1650-8.
8. Bab, I., Zimmer, A., and Melamed, E. (2009). Cannabinoids and the skeleton: from *Cannabis* to reversal of bone loss. *Annals of Medicine*. 41(8), 560-7.
9. Barnes, M.P. (2006, April). Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain. *Expert Opinion on Pharmacotherapy*, 7(5), 607-15.
10. Baron, E.P. (2015, June). Comprehensive Review of Medicinal Cannabis, Cannabinoids, and Therapeutic Implications in Medicine and Headache: What a Long Strange Trip It’s Been. *Headache*, 55(6), 885-916.
11. Beal, J.E., Olson, R., Laubenstein, L., Morales, J.O., Bellman, P., Yangco, B., Lefkowitz, L., Plasse, T.F., and Shephard, K.V. (1995, February). Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. *Journal of Pain and System Management*, 10(2), 89-97.
12. Bergamaschi, M.M., Queiroz, R.H., Chagas, M.H., de Oliveira, D.C., De Martinis, B.S., Kapczinski, F., Quevedo, J., Roesler, R., Schroder, N., Nardi, A.E., Martin-Santos, R., Hallak, J.E., Zuardo, A.W., and Crippa, J.A. (2011, May). Cannabidiol reduces the

- anxiety induced by simulated public speaking in treatment-naive social phobia patients. *Neuropsychopharmacology*, 36(6), 1219-26.
13. Betthausen, K., Pilz, J., and Vollmer, L.E. (2015, August). Use and effects of cannabinoids in military veterans with posttraumatic stress disorder. *American Journal of Health-System Pharmacy*, 72(15), 1279-84.
 14. Bilsland, L.G., Dick, J.R., Pryce, G., Petrosino, S., Di Marzo, V., Baker, D., and Greensmith, L. (2006). Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice. *The FASEB Journal*, 20(7), 1003-1005.
 15. Blair, R.E., Deshpande, L.S., and DeLorenzo, R.J. (2015, September). Cannabinoids: is there a potential treatment role in epilepsy? *Expert Opinion on Pharmacology*, 16(13), 1911-4.
 16. Borgelt, L.M., Franson, K.L., Nussbaum, A.M., and Wang, G.S. (2013, February). The pharmacologic and clinical effects of cannabinoids. *Pharmacotherapy*, 33(2), 195-209.
 17. Bossong, M.G., van Hell, H.H., Jager, G., Kahn, R.S., Ramsey, N.F., and Jansma, J.M. (2013, December). The endocannabinoid system and emotional processing: A pharmacological fMRI study with delta-9-tetrahydrocannabinol. *European Neuropsychopharmacology*, 23(12), 1687-1697.
 18. Burston, J.J., Sagar, D.R., Shao, P., Bai, M., King, E., Brailsford, L., Turner, J.M., Hathway, G.J., Bennett, A.J., Walsh, D.A., Kendall, D.A., Lichtman, A., and Chapman, V. (2013, November 25). Cannabinoid CB2 receptors regulate central sensitization and pain responses associated with osteoarthritis of the knee joint. *PLOS One*, doi: 10.1371/journal.pone.0080440.
 19. Campbell, V.A., and Gowran, A. (2007, November). Alzheimer's disease, taking the edge off with cannabinoids? *British Journal of Pharmacology*, 152(5), 655-662.
 20. Campos, A.C., Ferreira, F.R., and Guimaraes, F.S. (2012, November). Cannabidiol blocks long-lasting behavioral consequences of predator threat stress: possible involvement of 5Ht1A receptors. *Journal of Psychiatric Research*, 46(11), 1501-10.
 21. Cao, C., Li, Y., Liu, H., Bai, G., Mayl, J., Lin, X., Sutherland, K., Nabar, N., and Cai, J. (2014). The potential therapeutic effects of THC on Alzheimer's disease. *Journal of Alzheimer's Disease*, 42(3), 973-84.
 22. Carter, G.T., Abood, M.E., Aggarwal, S.K., and Weiss, M.D. (2010). Cannabis and amyotrophic lateral sclerosis: hypothetical and practical applications, and a call for clinical trials. *American Journal of Hospice & Palliative Medicine*, 27(5), 347-356.
 23. Castillo, A., Tolon, M.R., Fernandez-Ruiz, J., Romero, J., Martinez-Orgado, J. (2010, February). The neuroprotective effect of cannabidiol in an in vitro model of newborn hypoxic-ischemic brain damage in mice is mediated by CB(2) and adenosine receptors. *Neurobiology of Disease*, 37(2), 434-40.
 24. Chagas, M.H., Eckeli, A.L., Zuardi, A.W., Pena-Pereira, M.A., Sobreira-Neto, M.A., Sobreira, E.T., Camilo, M.R., Bergamaschi, M.M., Schenck, C.H., Hallack, J.E., Tumas, V., and Crippa, J.A. (2014, October). Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson's disease patients: a case series. *Journal of Clinical Pharmacy and Therapeutics*, 39(5), 564-6.
 25. Chagas, M.H., Zuardi, A.W., Tumas, V., Pena-Pereira, M.A., Sobreira, E.T., Bergamaschi, M.M., dos Santos, A.C., Teixeira, A.L., Hallak, J.E., and Crippa, J.A.

- (2014, November). Effects of cannabidiol in the treatment of patients with Parkinson's disease: an exploratory double-blind trial. *Journal of Psychopharmacology*, 29(11), 1088-98.
26. Clayton, N., Marshall, F.H., Bountra, C., and O'Shaughnessy, C.T. (2002, April). CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain. *Pain*, 96(3), 253-60.
 27. Colasanti, B.K., Craig, C.R., and Allara, R.D. (1984, September). Intraocular pressure, ocular toxicity and neurotoxicity after administration of cannabimol or cannabigerol. *Experimental Eye Research*, 39(3), 251-9.
 28. Collin, C., Ehler, E., Waberszinek, G., Alsindi, Z., Davies, P., Powell, K., Notcutt, W., O'Leary, C., Ratcliffe, S., Novakova, I., Zapletalova, O., Pikova, J., and Ambler, Z. (2010, June). A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. *Neurological Research*, 32(5), 451-9.
 29. Cota, D., Marsicano, G., Lutz, B., Vicennati, V., Stalla, G.K., Pasquali, R., and Pagotto, U. (2013, March). Endogenous cannabinoid system as a modulator of food intake. *International Journal of Obesity and Related Metabolic Disorders*, 27(3), 289-301.
 30. Crippa, J.A., Derenusson, G.N., Ferrari, T.B., Wichert-Ana, L., Duran, F.L., Martin-Santos, R., Simoes, M.V., Bhattacharyya, S., Fusar-Poli, P., Atakan, Z., Santos Filho, A., Freitas-Ferrari, M.C., McGuire, P.K., Zuardi, A.W., Busatto, G.F., and Hallak, J.E. (2011, January). Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. *Journal of Psychopharmacology*, 25(1), 121-30.
 31. Croxford, J.L., and Yamamura, T. (2005, September). Cannabinoids and the immune system: potential for the treatment of inflammatory diseases? *Journal of Neuroimmunology*, 166(1-2), 3-18.
 32. da Silva, V.K., de Freitas, B.S., da Silva Dornelles, A., Nery, L.R., Falavigna, L., Ferreira, R.D., Bogo, M.R., Hallak, J.E., Zuardi, A.W., Crippa, J.A., and Schroder, N. (2014, February). Cannabidiol normalizes caspase 3, synaptophysin, and mitochondrial fission protein DNM1L expression levels in rats with brain iron overload: implications for neuroprotection. *Molecular Neurobiology*, 49(1), 222-33
 33. De Filippis, D., Esposito, G., Cirillo, C., Cipriano, M., De Winter, B.Y., Scuderi, C., Sarnellil, G., Cuomo, R., Steardo, L., De Man, J.G., and Iuvone, T. (2011). Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis. *PLoS One*, 6(12), e28159.
 34. DeLong, G.T., Wolf, C.E., Poklis, A., and Lichtman, A.H. (2010, November 1). Pharmacological evaluation of the natural constituent of Cannabis sativa, cannabichromene and its modulation by (9)-tetrahydrocannabinol. *Drug and Alcohol Dependence*, 112(1-2), 126-33.
 35. de Mello Schier, A.R., de Oliveira Ribeiro, N.P., Coutinho, D.S., Machado, S., Arias-Carrion, O., Crippa, J.A., Zuardi, A.W., Nardi, A.E., and Silva, A.C. (2014). Antidepressant-like and anxiolytic-like effects of cannabidiol: a chemical compound of Cannabis sativa. *CNS & Neurological Disorders Drug Targets*, 13(6), 953-60.
 36. Devinsky, O., Cilio, M.R., Cross, H., Fernandez-Ruiz, J., French, J., Hill, C., Katz, R., Di Marzo, V., Jutras-Asward, D., Notcutt, W.G., Martinez-Orgado, J., Robson, P.J., Rohrback, B.G., Thiele, E., Whalley, B., and Friedman, D. (2014, June). Cannabidiol:

- pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. *Epilepsia*, 55(6), 791-802.
37. Durst, R., Danenberg, H., Gallily, R., Mechoulam, R., Meir, K., Grad, E., Beeri, R., Pugatsch, T., Tarsish, E., and Lotan, C. (2007, December). Cannabidiol, a nonpsychoactive Cannabis constituent, protects against myocardial ischemic reperfusion injury. *American Journal of Physiology: Heart and Circulatory Physiology*, 293(6), H3602-7.
 38. El-Alfy, A.T., Ivey, K., Robinson, K., Ahmed, S., Radwan, M., Slade, D., Khan, I., ElSohly, M., and Ross, S. (2010, June). Antidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from *Cannabis sativa* L. *Pharmacology, Biochemistry, and Behavior*, 95(4), 434-42.
 39. El-Remessy, A.B., Al-Shabrawey, M., Khalifa, Y., Tsai, N.T., Caldwell, R.B., and Liou, G.I. (2006, January). Neuroprotective and blood-retinal barrier-preserving effects of cannabidiol in experimental diabetes. *American Journal of Pathology*, 168(1), 235-44.
 40. Esposito, G., Filippis, D.D., Cirillo, C., Iuvone, T., Capoccia, E., Scuderi, C., Steardo, A., Cuomo, R., and Steardo, L. (2013, May). Cannabidiol in inflammatory bowel diseases: a brief overview. *Phytotherapy Research*, 27(5), 633-6.
 41. Farrimond, J.A., Whalley, B.J., and Williams, C.M. (2012, September). Cannabinol and cannabidiol exert opposing effects on rat feeding patterns. *Psychopharmacology*, 223(1), 117-29.
 42. Fernandez-Ruiz, J., Sagredo, O., Pazos, M.R., Garcia, C., Pertwee, R., Mechoulam, R., and Martinez-Orgado, J. (2013, February). Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid? *British Journal of Clinical Pharmacology*, 75(2), 323-33.
 43. Foldy, C., Malenka, R.C., and Sudhof, T.C. (2013, May 8). Autism-associated neuroligin-3 mutations commonly disrupt tonic endocannabinoid signaling. *Neuron*, 78(3), 498-509.
 44. Greco, R., Mangione, A.S., Sandrini, G., Nappi, G., and Tassorelli, C. (2014, March). Activation of CB2 receptors as a potential therapeutic target for migraine: evaluation in an animal model. *The Journal of Headache and Pain*, 15, 14.
 45. Greer, G.R., Grob, C.S., and Halberstadt, A.L. (2014, January-March). PTSD symptom reports of patients evaluated for the New Mexico Cannabinoids Program. *Journal of Psychoactive Drugs*, 46(1), 73-7.
 46. Gui, H., Liu, X., Wang, Z.W., He, D.Y., Su, D.F., and Dai, S.M. (2014). Expression of cannabinoid receptor 2 and its inhibitory effects on synovial fibroblasts in rheumatoid arthritis. *Rheumatology*, doi: 10.1093/rheumatology/ket447.
 47. Guzman, M. (2003, October). Cannabinoids: potential anticancer agents. *Nature Reviews*, 3(10), 745-55.
 48. Hong, J., Nandiwada, V., Jones, V., Lu, M., Warner, D.S., Mukhopadhyay, S., and Sheng, H. (2015, June 15). CB1 cannabinoid receptor agonist inhibits matrix metalloproteinase activity in spinal cord injury: A possible mechanism of improved recovery. *Neuroscience Letters*, 597, 19-24.
 49. Howard, J., Anie, K.A., Holdcroft, A., Korn, S. and Davies, S.C. (2005, October). Cannabis use in sickle cell disease: a questionnaire study. *British Journal of Haematology*, 131(1), 123-8.

50. Hussain, S.A., Zhou, R., Jacobson, C., Weng, J., Cheng, E., Lay, J., Hung, P., Lerner, J.T., and Sankar, R. (2015, June). Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: A potential role for infantile spasms and Lennox-Gastaut syndrome. *Epilepsy & Behavior*, 47, 138-41.
51. Idris, A.I., van't Hof, R.J., Greig, I.R., Ridge, S.A., Baker, D., Ross, R.A., and Ralston, S.H. (2005, July). Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors. *Nature Medicine*, 11(7), 774-9.
52. Idris, A.I., Sophocleous, A., Landao-Bassonga, E., van't Hof, R.J., and Ralston, S.H. (2008, November). Regulation of bone mass, osteoclast function, and ovariectomy-induced bone loss by the type 2 cannabinoid receptor. *Endocrinology*, 149(11), 5619-26.
53. Ignatowska-Jankowska, B., Jankowski, M.M., and Swiergiel, A.H. (2011, February 18). Cannabidiol decreases body weight gain in rats: involvement of CB2 receptors. *Neuroscience Letters*, 490(1), 82-4.
54. Iuvone, T., Esposito, G., Esposito, R., Santamaria, R., Di Rosa, M., and Izzo, A.A. (2004, April). Neuroprotective effect of cannabidiol, a non-psychoactive component from *Cannabis sativa*, on beta-amyloid-induced toxicity in PC12 cells. *Journal of Neurochemistry*, 89(1), 134-41.
55. Izzo, A.A., Capasso, R., Aviello, G., Borrelli, F., Romano, B., Piscitelli, F., Gallo, L., Capasso, F., Orlando, P., and De Marzo, V. (2012, June). Inhibitory effect of cannabichromene, a major non-psychoactive cannabinoid extracted from *Cannabis sativa*, on inflammation-induced hypermotility in mice. *British Journal of Pharmacology*, 166(4), 1444-60.
56. Jatoi, A., Windschitl, H.E., Loprinzi, C.L., Sloan, J.A., Dakhil, S.R., Mailliard, J.A., Pundaleeka, S., Kardinal, C.G., Fitch, T.R., Krook, J.E., Novotny, P.J., and Christensen, B. (2002). Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. *Journal of Clinical Oncology*, 20(2), 567-73.
57. Jensen, B., Chen, J., Furnish, T., and Wallace, M. (2015, October). Cannabinoids and Chronic Pain: a Review of Basic Science and Clinical Evidence. *Current Pain and Headache Reports*, 19(10), 524.
58. Johnson, J.R., Burnell-Nugent, M., Lossignol, D., Ganae-Motan, E.D., Potts, R., and Fallon, M.T. (2010, February). Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC: CBD extract and THC extract in patients with intractable cancer-related pain. *Journal of Pain and Symptom Management*, 39(2), 167-79.
59. Karniol, I.G., Shirakawa, I., Takahashi, R.N., Knobel, E., and Musty, R.E. (1975). Effects of delta9-tetrahydrocannabinol and cannabiniol in man. *Pharmacology*, 13(6), 502-12.
60. Kogan, N.M., Melamed, E., Wasserman, E., Raphael, B., Breuer, A., Stok, K. S., Sondergaard, R., Escudero, A. V., Baraghithy, S., Attar-Namdar, M., Friedlander-Barenboim, S., Mathavan, N., Isaksson, H., Mechoulam, R., Müller, R., Bajayo, A., Gabet, Y., and Bab, I. (2015). Cannabidiol, a Major Non-Psychoactive Cannabis Constituent Enhances Fracture Healing and Stimulates Lysyl Hydroxylase Activity in Osteoblasts. *Journal of Bone and Mineral Research*. doi: 10.1002/jbmr.2513.
61. Kohli, D.R., Li, Y., Khasabov, S.G., Gupta, P., Kehl, L.J., Ericson, M.E., Nguyen, J., Gupta, V., Hebbel, R.P., Simone, D.A., and Gupta, K. (2010, July 22). Pain-related

behaviors and neurochemical alterations in mice expressing sickle hemoglobin: modulation by cannabinoids. *Blood*, 116(3), 456-65.

62. Kozela, E., Lev., N., Kauschansky, N., Eilam, R., Rimmerman, N., Levy, R., Ben-Nun, A., Juknat, A., and Vogel, Z. (2011, August). Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorates multiple sclerosis-like disease in C57BL-6 mice. *British Journal of Pharmacology*, 163(7), 1507-19.
63. Kurz, R., and Blass, K. (2010). Use of dronabinol (delta-9-THC) in autism: A prospective single-case-study with an early infantile autistic child. *Cannabinoids*, 5(4), 4-6.
64. Kwiatkoski, M., Guimaraes, F.S., Del-Bel, E. (2012, April). Cannabidiol-treated rats exhibited higher motor score after cryogenic spinal cord injury. *Neurotoxicity Research*, 21(3), 271-80.
65. Lafuente, H., Alvarez, F.J., Pazos, M.R., Alvarez, A., Rey-Santano, M.C., Mielgo, V., Murgia-Esteve, X., Hilario, E., and Martinez-Orgado, J. (2011, September). Cannabidiol reduces brain damage and improves functional recovery after acute hypoxia-ischemia in newborn pigs. *Pediatric Research*, 70(3), 272-7.
66. Lakhan, S.E., & Rowland, M. (2009). Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review. *BMC Neurology*, 9, 59.
67. Le Foll, B., Trigo, J.M., Sharkey, K.A., and Le Strat, Y. (2013, May). Cannabis and delta9-tetrahydrocannabinol (THC) for weight loss? *Medical Hypothesis*, 80(5), 564-7.
68. Leweke, F.M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C.W., Hoyer, C., Klosterkotter, J., Hellmich, M., and Koeth, D. (2012). Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. *Translation Psychiatry*, 2, e94.
69. Ligresti, A., Moriello, A.S., Starowicz, K., Matias, I., Pisanti, S., De Petrocellis, L., Laezza, C., Portella, G., Bifulco, M., and Di Marzo, V. (2006, September). Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. *Journal of Pharmacology and Experimental Therapeutics*, 318(3), 1375-87.
70. Lim, M.P., Devi, L.A., and Rozenfeld, R. (2011). Cannabidiol causes activated hepatic stellate cell death through a mechanism of endoplasmic reticulum stress-induced apoptosis. *Cell Death & Disease*. Retrieved from <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3168994/>.
71. Limebeer, C.L., and Parker, L.A. (1999, December 16). Delta-9-tetrahydrocannabinol interferes with the establishment and the expression of conditioned rejection reactions produced by cyclophosphamide: a rat model of nausea. *Neuroreport*, 10(19), 3769-72.
72. Liu, W.M., Scott, K.A., Shamash, J., Joel, S., and Powles, T.B. (2008, September). Enhancing the in vitro cytotoxic activity of Delta9-tetrahydrocannabinol in leukemic cells through a combinatorial approach. *Leukemia & Lymphoma*, 49(9), 1800-9.
73. Lopez-Rodriguez, A.B., Siopi, E., Finn, D.P., Marchand-Leroux, C., Garcia-Segura, L.M., Jafarian-Tehrani, M., and Viveros, M.P. (2015, January). CB1 and CB2 cannabinoid receptor antagonists prevent minocycline-induced neuroprotection following traumatic brain injury in mice. *Cerebral Cortex*, 25(1), 35-45.
74. Lotan, I., Treves, T.A., Roditi, Y., and Djaldetti, R. (2014, March-April). Cannabis (medical Cannabis) treatment for motor and non-motor symptoms of Parkinson disease: an open-label observational study. *Clinical Neuropharmacology*, 37(2), 41-4.
75. Maa, E., and Figi, P. (2014, June). The case for medical Cannabis in epilepsy. *Epilepsia*, 55(6), 783-6.

76. Maione, S., Piscitelli, F., Gatta, L., Vita, D., De Petrocellis, L., Palazzo, E., de Novellis, V., and Di Marzo, V. (2011, February). Non-psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action. *British Journal of Pharmacology*, 162(3), 584-96.
77. Malfait, A.M., Gallily, R., Sumariwalla, P.F., Malik, A.S., Andreakos, E., Mechoulam, R., and Feldmann, M. (2000). The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. *Proceedings of the National Academy of Sciences of the United States of America*, 97(17), 9561–9566.
78. Martin-Moreno, A.M., Reigada, D., Ramirez, B.G., Mechoulam, R., Innamorato, N., Cuadrado, A., and de Ceballos, M.L. (2011, June). Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer's disease. *Molecular Pharmacology*, 79(6), 964-73.
79. McAllister, S.D., Christian, R.T., Horowitz, M.P., Garcia, A., and Desprez, P.Y. (2007, November). Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells. *Molecular Cancer Therapeutics*, 6(11), 2921-7.
80. McAllister, S.D., Murase, R., Christian, R.T., Lau, D., Zielinski, A.J., Allison, J., Almanza, C., Pakdel, A., Lee, J., Limbad, C., Liu, Y., Debs, R.J., Moore, D.H., and Desprez, P.Y. (2011, August). Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis. *Breast Cancer Research and Treatment*, 129(1), 37-47.
81. McAllister, S.D., Soroceanu, L., and Desprez, P.Y. (2015, June). The Antitumor Activity of Plant-Derived Non-Psychoactive Cannabinoids. *Journal of Neuroimmune Pharmacology*, 10(2), 255-67.
82. Mecha, M., Feliu, A., Inigo, P.M., Mestre, L., Carrillo-Salinas, F.J., and Guaza, C. (2013, November). Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: a role for A2A receptors. *Neurobiology of Disease*, 59, 141-50.
83. Mechoulam, R., and Shohami, E. (2007, August). Endocannabinoids and traumatic brain injury. *Molecular Neurobiology*, 36(1), 68-74.
84. Mukhopadhyay, P., Monanraj, R., and Pacher, P. (2011, May 15). Cannabidiol protects against hepatic ischemia/reperfusion injury by attenuating inflammatory signaling and response, oxidative/nitrative stress, and cell death. *Free Radical Biology & Medicine*, 50(10), 1368-1381.
85. Nadolska, K., and Gos., R. (2008). Possibilities of applying cannabinoids' in the treatment of glaucoma. *Klinika Oczna*, 110(7-9), 314-7.
86. Naftali, T., Bar-Lev Schleider, L., Dotan, I., Lansky, E.P., Sklerovsky Benjaminov, F., and Konikoff, F.M. (2013, October). Cannabis induces a clinical response in patients with Crohn's disease: a prospective placebo-controlled study. *Clinical Gastroenterology and Hepatology*, 11(10), 1276-1280.
87. Nagarkatti, P., Pandey, R., Rieder, S.A., Hegde, V.L., and Nagarkatti, M. (2009, October). Cannabinoids as novel anti-inflammatory drugs. *Future Medicinal Chemistry*, 1(7), 1333-49.
88. Nakajima, J., Nakae, D., and Yasukawa, K. (2013, August). Structure-dependent inhibitory effects of synthetic cannabinoids against 12-O-tetradecanoylphorbol-13-acetate-induced inflammation and skin tumour promotion in mice. *Journal of Pharmacy and Pharmacology*, 65(8), 1223-1230.

89. Nauck, F., Klaschik, E. (2004, June). Cannabinoids in the treatment of the cachexia-anorexia syndrome in palliative care patients. *Schmerz*, 18(3), 197-202.
90. Nelson, K., Walsh, D., Deeter, P., and Sheehan, F. (1994). A phase II study of delta-9-tetrahydrocannabinol for appetite stimulation in cancer-associated anorexia. *Journal of Palliative Care*, 10(1), 14-8.
91. Nguyen, B.M., Kim, D., Bricker, S., Bongard, F., Neville, A., Putnam, B., Smith J., and Plurad, D. (2014, October). Effect of Cannabis use on outcomes in traumatic brain injury. *The American Surgeon*, 80(10), 979-83.
92. Ofek, O., Karsak, M., Leclerc, N., Fogel, M., Frenkel, B., Wright, K., Tam, J., Attar-Namdar, M., Kram, V., Shohami, E., Mechoulam, R., Zimmer, A., and Bab, I. (2006, January 17). Peripheral cannabinoid receptor, CB2, regulates bone mass. *Proceedings of the National Academy of Sciences of the United States of America*, 103(3), 696-701.
93. Orellana-Serradell, O., Poblete, C.E., Sanchez, C., Castellon, E.A., Gallegos, I., Huidobro, C., Llanos, M.N., and Contreras, H.R. (2015, April). Proapoptotic effect of endocannabinoids in prostate cancer cells. *Oncology Reports*, 33(4), 1599-608.
94. Parker, L.A., Rock, E.M., and Limbeer, C.L. (2011, August). Regulation of nausea and vomiting by cannabinoids. *British Journal of Pharmacology*, 163(7), 1411-22.
95. Passie, T., Emrich, H.M., Karst, M., Brandt, S.D. and Halpern, J.H. (2012, July-August). Mitigation of post-traumatic stress symptoms by Cannabis resin: a review of the clinical and neurobiological evidence. *Drug Testing and Analysis*, 4(7-8), 649-59.
96. Pazos, M.R., Mohammed, N., Lafuente, H., Santos, M., Martinez-Pinilla, E., Moreno, E., Valdizan, E., Romero, J., Pazos, A., Franco, R., Hillard, C.J., Alvarez, F.J., Martinez-Orgado, J. (2013, August). Mechanisms of cannabidiol neuroprotection in hypoxic-ischemic newborn pigs: role of 5HT(1A) and CB2 receptors. *Neuropharmacology*, 71, 282-91.
97. Pinar-Sueiro, S., Rodriguez-Puertas, R., and Vecino, E. (2011, January). Cannabinoid applications in glaucoma. *Archivos de la Sociedad Espanola de Oftalmologia*, 86(1), 16-23.
98. Porter, B.E., and Jacobson, C. (2013, December). Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy. *Epilepsy & Behavior*, 29(3), 574-7.
99. Powles, T., te Poele, R., Shamash, J., Chaplin, T., Propper, D., Joel, S., Oliver, T., and Liu, W.M. (2005, February 1). Cannabis-induced cytotoxicity in leukemia cell lines: the role of the cannabinoid receptors and the MAPK pathway. *Blood*, 105(3), 1214-21.
100. Rajavashisth, T.B., Shaheen, M., Norris, K.C., Pan, D., Sinha, S.K., Oretaga, J., Friedman, T.C. (2012). Decreased prevalence of diabetes in Cannabis users: cross-sectional data from the National Health and Nutrition Examination Survey (NHANES) III. *BMJ Open*, 2, e000494.
101. Rajesh, M., Mukhopadhyay, P., Batkai, S., Patel, V., Saito, K., Matsumoto, S., Kashiwaya, Y., Horvath, B., Mukhopadhyay, B., Becker, L., Hasko, G., Liudet, L., Wink, D.A., Veves, A., Mechoulam, R., and Pacher, P. (2010, December 14). Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy. *Journal of the American College of Cardiology*, 56(25), 2115-25.
102. Raman, C., McAllister, S.D., Rizvi, G., Patel, S.G., Moore, D.H., and Abood, M.E. (2004). Amyotrophic lateral sclerosis: delayed disease progression in mice by

- treatment with a cannabinoid. *Amyotrophic Lateral Sclerosis & Other Motor Neuron Disorders*, 5(1), 33-30.
103. Ramikie, T.S., Nyilas, R., Bluett, R.J., Gamble-George, J.C., Hartley, N.D., Mackie, K., Watanabe, M., Katona, I., and Patel, S. (2014, March 5). Multiple mechanistically distinct modes of endocannabinoid mobilization of central amygdala glutamatergic synapses. *Neuron*, 81(5), 1111-25.
 104. Ramirez, B.G., Blazquez, C., Gomez del Pulgar, T., Guzman, M., and de Ceballos, M.L. (2005, February). Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. *Journal of Neuroscience*, 25(8), 1904-13.
 105. Ravikoff Allegretti, J., Courtwright, A., Lucci, M., Korzenik, J.R., and Levine, J. (2013, December). Cannabis use patterns among patients with inflammatory bowel disease. *Inflammatory Bowel Diseases*, 19(13), 2809-14.
 106. Rog, D.J., Nurmikko, T.J., and Young, C.A. (2007, September). Oromucosal delta9-tetrahydrocannabinol-cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial. *Clinical Therapeutics*, 29(9), 2068-79.
 107. Rosenberg, E.C., Tsien, R.W., Whalley, B.J., and Devinsky, O. (2015, August 18). Cannabinoids and Epilepsy. *Neurotherapeutics*, Epub ahead of print. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/26282273>.
 108. Salazar, M., Carracedo, A., Salanueva, Í.J., Hernández-Tiedra, S., Lorente, M., Egia, A., Vazquez, P., Blazquez, C., Torres, S., Garcia, S., Nowak, J., Fimia, G.M., Piacentini, M., Cecconi, F., Pandolfi, P.P., Gonzalez-Geria, L., Iovanna, J.L., Guzman, M., Boya, P., and Velasco, G. (2009). Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells. *The Journal of Clinical Investigation*, 119(5), 1359–1372. <http://doi.org/10.1172/JCI37948>
 109. Shinjyo, N., and Di Marzo, V. (2013, November). The effect of cannabichromene on adult neural stem/progenitor cells. *Neurochemistry International*, 63(5), 432-437.
 110. Scutt, A., and Willilamson, E.M. (2007). Cannabinoids stimulate fibroblastic colony formation by bone marrow cells indirectly via CB2 receptors. *Calcified Tissue International*, 80, 50-59.
 111. Signorelli, A.A., Ribeiro, S.B., Moraes-Souza, H., de Oliveira, L.F., Ribeiro, J.B., da Silva, S.H., de Oliveira, D.F., and Ribeiro, MF. (2013). Pain measurement as part of primary healthcare of adult patients with sickle cell disease. *Revista Brasileira de Hematologia e Hemoterapia*, 35(4), 272-7.
 112. Silvestri, C., Paris, D., Martella, A., Melck, D., Guadagnino, I., Cawthorne, M., Motta, A., and Di Marzo, V. (2015, June). Two non-psychoactive cannabinoids reduce intracellular lipid levels and inhibit hepatosteatosis. *Journal of Hepatology*, 62(6), 1382-900.
 113. Syed, Y.Y., McKeage, K., and Scott, L.J. (2014, April). Delta-9-tetrahydrocannabinol-cannabidiol (Sativex): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis. *Drugs*, 74(5), 563-78.
 114. Szaflarski, J.P., and Bebin, E.M. (2014, December). Cannabis, cannabidiol, and epilepsy—from receptors to clinical response. *Epilepsy & Behavior*, 41, 277-82.
 115. Takahashi, R.N., Karniol, I.G. (1975). Pharmacologic interaction between cannabiniol and delta9-tetrahydrocannabinol. *Psychopharmacologia*, 41(3), 277-84.

116. Takeda, S., Okazaki, H., Ikeda, E., Abe, S., Yoshioka, Y., Watanabe, K., and Aramaki, H. (2014). Down-regulation of cyclooxygenase-2 (COX-2) by cannabidiolic acid in human breast cancer cells. *The Journal of Toxicological Sciences*, 39(5), 711-6.
117. Trezza, V., and Campolongo, P. (2013, August 9). The endocannabinoid system as a possible target to treat both the cognitive and emotional features of post-traumatic stress disorder (PTSD). *Frontiers in Behavioral Neuroscience*, 7, 100.
118. Tripp, D.A., Nickel, J.C., Katz, L., Krsmanovic, A., Ware, M.A., and Santor, D. (2014, November). A survey of cannabis (Cannabis) use and self-reported benefit in men with chronic prostatitis/chronic pelvic pain syndrome. *Canadian Urological Association Journal*, 8(11-12). Retrieved from <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4277530/>.
119. Turner, C.D., and Elsohly, M.A. (1981, August-September). Biological activity of cannabichromene, its homologs and isomers. *Journal of Clinical Pharmacology*, 21 (8-9 Suppl), 238S-291S.
120. Usami, N., Kobana, K., Yoshida, H., Kimura, T., Watanabe, K., Yoshimura, H., and Yamamoto, I. (1998, September). Synthesis and pharmacological activities in mice of halogenated delta 9-tetrahydrocannabinol derivatives. *Chemical & Pharmaceutical Bulletin*, 46(9), 1462-7.
121. Wade, D.T., Robson, P., House, H., Makela, P., and Aram, J. (2003, February). A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. *Clinical Rehabilitation*, 17(1), 21-9.
122. Ware, M.A., Doyle, C.R., Woods, R., Lynch, M.E., and Clark, A.J. (2003, March). Cannabis use for chronic non-cancer pain: results of a prospective survey. *Pain*, 102(1-2).
123. Wargent, E.T., Zaibi, M.S., Silvestri, C., Hislop, D.C., Stocker, C.J., Stott, C.G., Guy, G.W., Duncan, M., Di Marzo, V., and Cawthorne, M.A. (2013, May 27). The cannabinoid 9-tetrahydrocannabinol (THCV) ameliorates insulin sensitivity in two mouse models of obesity. *Nutrition & Diabetes*, 3, e68.
124. Whyte, L.S., Ford, L., Ridge, S.A., Cameron, G.A., Rogers, M.J., and Ross, R.A. (2012, April). Cannabinoids and bone: endocannabinoids modulate human osteoclast function in vitro. *British Journal of Pharmacology*. 165(8), 2584-97.
125. Weiss, L., Zeira, M., Reich, S., Har-Noy, M., Mechoulam, R., Slavin, S., and Gallily, R. (2006, March). Cannabidiol lowers incidence of diabetes in non-obese diabetic mice. *Autoimmunity*, 39(2), 143-51.
126. Weiss, L., Zeira, M., Reich, S., Slavin, S., Raz, I., Mechoulam, R., and Gallily, R. (2008, January). Cannabidiol arrests onset of autoimmune diabetes in NOD mice. *Neuropharmacology*, 54(1), 244-9.
127. Weydt, P., Hong, S., Witting, A., Moller, T., Stella, N. and Klot, M. (2005). Cannabidiol delays symptom onset in SOD1 transgenic mice without affecting survival. *Amyotrophic Lateral Sclerosis & Other Motor Neuron Disorders*, 6(3), 182-184.
128. Wirth, P.W., Watson, E.S., ElSohly, M., Turner, C.E., and Murphy, J.C. (1980, June 9). Anti-inflammatory properties of cannabichromene. *Life Sciences*, 26(23), 1991-5.
129. Yeshurun, M., Shpilberg, O., Herscovici, C., Shargian, L., Dreyer, J., Peck, A., Israeli, M., Levy-Assaraf, M., Gruenewald, T., Mechoulam, R., Raanani, P., and Ram, R. (2015, October). Cannabidiol for the Prevention of Graft-versus-Host-Disease after

Allogeneic Hematopoietic Cell Transplantation: Results of a Phase II Study. *Biology of Blood and Marrow Transplantation*, 21(10), 1770-5.

130. Yoshida, H., Usami, N., Ohishi, Y, Watanabe, K., Yamamoto, I., and Yoshimura, H. (1995, February). Synthesis and pharmacological effects in mice of halogenated cannabinol derivatives. *Chemical & Pharmaceutical Bulletin*, 43(2), 335-7.
131. Zanelati, T.V., Biojone, C., Moreira, F.A., Guimaraes, F.S., and Joca, S.R. (2010, January). Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors. *British Journal of Pharmacology*, 159(1), 122-8.
132. Zeissler, M.L., Eastwood, J., Hanemann, C.O., Zajicek, J., and Carroll, C., (2013). 9-Tetrahydrocannabinol is protective through PPAR γ dependent mitochondrial biogenesis in a cell culture model of Parkinson's disease. *Journal of Neurology, Neurosurgery and Psychiatry*, 84.
133. Zuardi, A.W., Crippa, J.A., Hallak, J.E., Moreira, F.A., and Guimaraes, F.S. (2006, April). Cannabidiol, a *Cannabis sativa* constituent, as an antipsychotic drug. *Brazilian Journal of Medical and Biological Research*, 39(4), 421-9.
134. Zuardi, A.W., (2008, September). Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. *Revista Brasileira De Psiquiatria*, 30(3), 271-80.
135. Zuardi, A.W., Crippa, J.A., Hallak, J.E., Pinto, J.P., Chagas, M.H., Rodrigues, G.G., Dursun, S.M., and Tumas, V. (2009, November). Cannabidiol for the treatment of psychosis in Parkinson's disease. *Journal of Psychopharmacology*, 23(8), 979-83.
136. Zygmunt, P.M., Andersson, D.A., and Hogestatt, E.D. (2002, June 1). 9-Tetrahydrocannabinol and Cannabinol Activate Capsaicin-Sensitive Sensory Nerves via a CB1 and CB2 Cannabinoid Receptor-Independent Mechanism. *The Journal of Neuroscience*, 22(11), 4720-4727